Cancer proteomics start-up TheRyte catches Randox's eye
This article was originally published in Clinica
A company that was spun out of the University of Liverpool, UK, has netted a deal with the nation's largest clinical diagnostics manufacturer. Randox Laboratories has signed a licence and commercialisation agreement for TheRyte's proteomics-based tests for cancer. It has also bought an equity stake in the firm, which was formed in 1997.